source
- Rezera files for IPO to fund NLRP3 peripheral artery disease programRezera, which rebranded from NodThera earlier this year, has entered the queue for an initial public offering. The filing, submitted on Wednesday, is intended to raise capital to support the compa…
- Regeneron explores pairing its obesity drug with lipid-lowering therapy to differentiate in crowded GLP-1 marketThe pipeline of GLP-1 based medicines is delivering increasingly strong weight-loss results, prompting many companies to seek ways to stand out as the market fills. Regeneron said it is looking at…